2 Information about brexucabtagene autoleucel

Marketing authorisation indication

2.1 Brexucabtagene autoleucel (Tecartus, Kite) is indicated for 'the treatment of adult patients 26 years of age and above with relapsed or refractory B cell precursor acute lymphoblastic leukaemia'.

2.2 The dosage schedule is available in the summary of product characteristics for brexucabtagene autoleucel.


2.3 The list price for single infusion is £316,118 (excluding VAT, MIMS [Monthly Index of Medical Specialities] online, accessed February 2023).

2.4 The company has a commercial arrangement. This makes brexucabtagene autoleucel available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)